RxDoctor Payments DataLook up a doctor →

Grace Stonerock, MD

Family Medicine · Manassas, VANPI 1629234489

Payments from drug & device makers

$18,124in general payments, 2019–2025

Across 1,101 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • GSK$977
  • plus $8K from 40 others

What the payments were for

  • Food & beverage$18,00099%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,124 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$128,622
Medicare patients
262
Services billed
1,565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$99,918
FarxigaDapagliflozin Propanediol69$82,463
TrulicityDulaglutide26$43,644
Soliqua 100-33Insulin Glargine/Lixisenatide42$37,506
EliquisApixaban24$36,795
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$28,131
MyrbetriqMirabegron17$22,837
XareltoRivaroxaban22$22,359
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$18,247
Repatha SureclickEvolocumab11$13,488
SymbicortBudesonide/Formoterol Fumarate46$13,025
Raloxifene Hcl112$4,123
Montelukast Sodium280$3,297
Levothyroxine Sodium318$3,297
Atorvastatin Calcium403$3,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,392$99,91887 claims
AstraZenecaFarxiga, Symbicort$2,822$95,488115 claims
Lilly USA, LLCTrulicity$1,091$43,64426 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$936$37,50642 claims
PfizerEliquis$1,316$36,79524 claims
GSKTrelegy Ellipta$977$28,13133 claims
Astellas Pharma US IncMyrbetriq$341$22,83717 claims
Johnson & JohnsonXarelto$169$22,35922 claims
AbbVieSynthroid$1,603$2,35938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →